IARC: Microwave News Article Archive (2004 - )

It has been nearly eight years since an expert panel of the International Agency for Research on Cancer (IARC) classified RF radiation as a possible human carcinogen. Since then, neither the World Health Organization (WHO) nor the International Commission on Non-Ionizing Radiation Protection (ICNIRP) has recommended precautionary policies to limit potential health risks.

No U.S. health agency has yet advised the public to reduce RF exposures.

Even after two large animal studies —by the U.S. National Toxicology Program (NTP) and Italy’s Ramazzini Institute— presented clear evidence of a cancer link last year, the WHO has remained silent; ICNIRP responded by calling both animal studies unconvincing.

Now comes the Annual Review of Public Health, which on January 11 posted a paper by five leading epidemiologists who posit that, after a systematic review of all the human studies, they don’t see an elevated cancer risk. The takeaway is that the IARC classification was a mistake.

The RF–cancer story took a remarkable turn a few days ago. A new animal study challenged many of the assumptions which lie at the heart of claims that RF radiation —whether from cell phones, cell towers or Wi-Fi— are safe.

The new study, from Germany, a replication of an earlier experiment, also from Germany, found that weak cell phone signals can promote the growth of tumors in mice. It used radiation levels that do not cause heating and are well below current safety standards. Complicating matters even further, lower doses were often found to be more effective tumor promoters than higher levels; in effect, turning the conventional concept of a linear dose-response on its head.

Just over a year ago, the Danish Cancer Society (DCS) issued a news advisory with some alarming news: The number of men diagnosed with glioblastoma, the most malignant type of brain cancer, had doubled over the last ten years. Hans Skovgaard Poulsen, the head of neuro-oncology at Copenhagen University Hospital was quoted in the release as saying that this was a “frightening development.”

At the time, Christoffer Johansen, a senior researcher at the DCS told us: “I think the data is true and valid.” And Joachim Schüz, a long time collaborator of Johansen’s at the DCS who is now at the International Agency for Research on Cancer (IARC) in Lyon told Microwave News that the news was “indeed a concern.” He said that he could not explain it. (See our report here.)

After that, there was silence.

A new analysis from the U.S. National Cancer Institute has found that the rates of brain tumors (glioma) in the United States are inconsistent with the results of Lennart Hardell’s group in Sweden. The NCI team, led by Mark Little, does allow that “the U.S. data could be consistent with the modest excess risks in the Interphone study.’’